CANADA LIFE ASSURANCE Co Decreases Holdings in SI-BONE, Inc. (NASDAQ:SIBN)

CANADA LIFE ASSURANCE Co lessened its holdings in shares of SI-BONE, Inc. (NASDAQ:SIBN - Free Report) by 84.6% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 3,880 shares of the company's stock after selling 21,307 shares during the period. CANADA LIFE ASSURANCE Co's holdings in SI-BONE were worth $54,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. American Century Companies Inc. lifted its stake in SI-BONE by 11.0% in the fourth quarter. American Century Companies Inc. now owns 2,378,068 shares of the company's stock valued at $33,341,000 after buying an additional 236,167 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of SI-BONE by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 933,891 shares of the company's stock worth $13,097,000 after acquiring an additional 9,847 shares during the period. Harbor Capital Advisors Inc. increased its position in SI-BONE by 35.5% during the 4th quarter. Harbor Capital Advisors Inc. now owns 841,045 shares of the company's stock worth $11,791,000 after buying an additional 220,555 shares during the period. Impax Asset Management Group plc increased its holdings in shares of SI-BONE by 1.1% during the fourth quarter. Impax Asset Management Group plc now owns 766,761 shares of the company's stock worth $10,750,000 after purchasing an additional 8,240 shares during the period. Finally, Pier Capital LLC grew its stake in SI-BONE by 1.6% during the fourth quarter. Pier Capital LLC now owns 473,123 shares of the company's stock worth $6,633,000 after buying an additional 7,225 shares in the last quarter. 98.11% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Truist Financial reiterated a "buy" rating and set a $22.00 price target (up previously from $18.00) on shares of SI-BONE in a report on Tuesday, February 25th. Needham & Company LLC reaffirmed a "buy" rating and set a $24.00 target price on shares of SI-BONE in a research report on Tuesday. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $25.00 price target on shares of SI-BONE in a research report on Tuesday. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $24.40.

Insiders Place Their Bets

In other SI-BONE news, insider Anthony J. Recupero sold 3,311 shares of the stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $14.15, for a total transaction of $46,850.65. Following the completion of the transaction, the insider now owns 284,555 shares of the company's stock, valued at $4,026,453.25. This represents a 1.15 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Michael A. Pisetsky sold 3,128 shares of the firm's stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $14.14, for a total value of $44,229.92. Following the completion of the sale, the senior vice president now directly owns 244,878 shares of the company's stock, valued at $3,462,574.92. This trade represents a 1.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 6,775 shares of company stock valued at $95,711. Insiders own 3.90% of the company's stock.

SI-BONE Stock Performance

Shares of SIBN traded up $1.78 during trading hours on Tuesday, hitting $16.03. The stock had a trading volume of 395,519 shares, compared to its average volume of 372,844. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22. SI-BONE, Inc. has a 12 month low of $11.70 and a 12 month high of $19.16. The firm has a market capitalization of $681.53 million, a PE ratio of -17.40 and a beta of 0.82. The stock has a fifty day moving average price of $14.53 and a 200 day moving average price of $14.69.

SI-BONE (NASDAQ:SIBN - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported ($0.15) EPS for the quarter, beating analysts' consensus estimates of ($0.24) by $0.09. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. The firm had revenue of $47.29 million during the quarter, compared to the consensus estimate of $45.13 million. Analysts anticipate that SI-BONE, Inc. will post -0.78 EPS for the current year.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.